Michael F. Manion

Filings by Michael F. Manion span 2 companies, the busiest being Theriva Biologics, Inc. and Uromed Corp. Over a trading history stretching from 31 May 2006 to 21 December 2007, the count stands at 6 filings.

The open-market side counts 1 purchase for €7,298 alongside 2 sales for €175k. Taken together, the sales exceed the purchases by €167k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 2 share grants. Since January 2008: no purchases and 2 sales on the market.

The record was last updated on 2 January 2008 with an open-market sale (€17k) in Uromed Corp. The most recent open-market purchase was published on 1 June 2006, 7,450 days ago. The median gap between a trade and its publication by SEC (Form 4) is 12 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.